News items related to:

  • Abacavir – ABC

    Abacavir is recommended by WHO as a component of first and second-line antiretroviral treatment regimens for infants and children. Abacavir is commonly known as ABC.

  • Atazanavir – ATV

    Atazanavir (boosted with ritonavir) is recommended by WHO as a component of second-line antiretroviral treatment regimens in adults. Atazanavir is also known as ATV.

  • Darunavir – DRV

    Darunavir (boosted with ritonavir) is recommended by WHO as a component of third-line antiretroviral treatment regimens, and as an alternative to second-line regimens for adults. Duranavir is also known as DRV.

  • Dolutegravir – DTG

    Dolutegravir was approved by the United States Food and Drug Administration in 2013. Dolutegravir is also known as DTG.

  • Efavirenz – EFV

    Efavirenz is recommended by WHO as a component of first-line antiretroviral treatment regimens for adults, and as a component of first- and second-line treatment regimens for children over three years of age. Efavirenz is also commonly known as EFV.

  • Emtricitabine – FTC

    Emtricitabine is recommended by WHO as a component of first-line antiretroviral treatment regimens and as an alternative in second-line regimens for adults. It is also an alternative component in first- and second-line regimens for children. Emtricitabine is also commonly known as FTC.

  • Etravirine – ETV

    Summary There are no pharmaceutical companies manufacturing generic etravirine. Given the patent coverage in key manufacturing countries, it is likely...

  • Lopinavir – LPV

    Lopinavir, boosted with ritonavir, is recommended by WHO as a component of second-line antiretroviral treatment regimens for adults and children, and as a component of the first-line treatment regimen for children under three. Lopinavir is commonly known as LPV.

  • Raltegravir – RAL

    Raltegravir is recommended by WHO as a component of third-line antiretroviral treatment regimens. Raltegravir is also commonly referred to as RAL.

  • Rilpivirine – RPV

    Rilpivirine was approved by the United States Food and Drug Administration in 2011. It is not currently included in the WHO guidelines. Rilpivirine is also commonly known as RPV.

  • Ritonavir – RTV

    Ritonavir is recommended by WHO as a booster for atazanavir, lopinavir and darunavir. Ritonavir is also commonly known as RTV or r.

  • Tenofovir alafenamide – TAF

    Tenofovir alafenamide is a pro-drug of tenofovir, which has been submitted for regulatory approval in combination with emtricitabine and as part of a single-tablet regimen comprising TAF/FTC/EVG/ COBI. Tenofovir alafenamide is commonly known as TAF.